Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition

被引：5

作者：

Deak, Laura Codarri ^{[1
]}

Hashimoto, Masao ^{[2
,3
]}

Umana, Pablo ^{[1
]}

Klein, Christian ^{[1
]}

机构：

[1] Roche Pharm Res & Early Dev, Roche Innovat Ctr Zurich, Canc Immunotherapy Discovery, Roche Glycart AG Wagistr 10, CH-8952 Schlieren, Switzerland

[2] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA USA

[3] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA USA

来源：

ONCOIMMUNOLOGY | 2023年 / 12卷 / 01期

关键词：

Eciskafusp alfa; IL-2; PD-1; PD1-IL2v; RG6279; TCF-1; CYTOKINE;

D O I：

10.1080/2162402X.2023.2197360

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The immunocytokine PD1-IL2v was designed to overcome liabilities and improve efficacy of IL-2 therapies. PD1-IL2v preferentially targets PD-1(+) T-cells and acts on antigen-specific stem-like PD-1(+) TCF-1(+) CD8(+) T-cells expanding and differentiating them towards better effectors resulting in superior efficacy in LCMV chronic infection and tumor models compared to checkpoint inhibition.

引用

页数：3

共 25 条

[1] Effect of a novel anti-PD-1-proIL-2 bifunctional fusion protein on potent anti-tumor activity via PD-1 checkpoint inhibition and conditional IL-2R agonism
Zhou, Harry
Li, Zijuan
Zhang, Feifei
Zhang, Ze
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] INHIBITION OF INTERLEUKIN-1 (ALPHA AND BETA), INTERLEUKIN-2 SECRETION AND SURFACE EXPRESSION OF INTERLEUKIN-2 RECEPTOR (IL-2R) BY A NOVEL CYTOKINE INTERLEUKIN-1 RECEPTOR ANTAGONIST (IL-1RA)
CONTI, P
PANARA, MR
PORRINI, AM
GAMBI, D
BARBACANE, RC
REALE, M
BONGRAZIO, M
DEMPSEY, RA
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1992, 36 (01) : 27 - 33
[3] Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
Ziogas, Dimitrios C.
Theocharopoulos, Charalampos
Lialios, Panagiotis-Petros
Foteinou, Dimitra
Koumprentziotis, Ioannis-Alexios
Xynos, Georgios
Gogas, Helen
CANCERS, 2023, 15 (10)
[4] A novel anti-PD1-IL15 immunocytokine potentiates anti-tumor T cell activity of PD-1 checkpoint inhibition and IL-2R-beta-gamma agonism
Lu, Dan
Polonskaya, Zhanna
Chang, Tzi-Pei
Martomo, Stella
Luna, Xenia
Zhang, Zhikai
Miyara, Faical
Patel, Jeedar
CANCER RESEARCH, 2020, 80 (16)
[5] A novel anti-PD-1 and proIL-2 bifunctional fusion protein delivers potent anti-tumor activity via PD-1 checkpoint inhibition and tumor selective IL-2R agonism preferentially on antigen specific T cells
Li, Zijuan
Zhang, Feifei
Zhang, Ze
Zhou, Harry
CANCER RESEARCH, 2024, 84 (06)
[6] Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
Schmittnaegel, Martina
Rigamonti, Nicolo
Kadioglu, Ece
Cassara, Antonino
Rmili, Celine Wyser
Kiialainen, Anna
Kienast, Yvonne
Mueller, Hans-Joachim
Ooi, Chia-Huey
Laoui, Damya
De Palma, Michele
SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (385)
[7] MECHANISM OF ACTION OF INTERLEUKIN-2 RECEPTOR (IL-2R) MONOCLONAL-ANTIBODY (MAB) THERAPY - TARGET-CELL DEPLETION OR INHIBITION OF FUNCTION
TELLIDES, G
DALLMAN, MJ
MORRIS, PJ
TRANSPLANTATION PROCEEDINGS, 1989, 21 (01) : 997 - 998
[8] Novel immune-cell targeted IL2v to deliver IL-2R signaling to tumor reactive T cells via PD-1 whilst blocking the PD-1 pathway
Deak, Laura Codarri
Nicolini, Valeria
Lauener, Laura
Seeber, Stefan
Richard, Marine
Bommer, Esther
Karagianni, Maria
Sam, Johannes
Schlenker, Ramona
Mariani, Marisa
Schwalie, Petra
Herter, Sylvia
Bacac, Marina
Waldhauer, Inja
Freimoser-Grundschober, Anne
Teichgraber, Volker
Klein, Christian
Umana, Pablo
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[9] A novel dual mechanism-of-action bispecific PD-1-IL-2v armed by a "βγ-only" interleukin-2 variant
Jiang, Yongji
Chen, Chuyuan
Liu, Yuan
Wang, Rong
Feng, Chuan
Cai, Lili
Chang, Shuang
Zhao, Lei
FRONTIERS IN IMMUNOLOGY, 2024, 15
[10] Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade
Victoria Klepsch
Natascha Hermann-Kleiter
Patricia Do-Dinh
Bojana Jakic
Anne Offermann
Mirjana Efremova
Sieghart Sopper
Dietmar Rieder
Anne Krogsdam
Gabriele Gamerith
Sven Perner
Alexandar Tzankov
Zlatko Trajanoski
Dominik Wolf
Gottfried Baier
Nature Communications, 9

← 1 2 3 →